Once renowned as the vehicle for controversial tycoon Tiny Rowland’s corporate manoeuvres, AIM-quoted Lonrho Africa is in the throes of another strategic realignment. David Lenigas, the Australian resource-focused entrepreneur who became chief executive officer in December, wants to take the company back to its roots by ‘re-establishing a significant presence in the continent of Africa’.
As a first step, Lonrho has agreed to pay £5 million for a ten per cent stake in Brinkley Mining, which holds the rights to 162 square miles of uranium and molybdenum-bearing land in South Africa’s Karoo region, some 280 miles north-east of Cape Town. Brinkley, which is itself poised to float on AIM, is ‘likely’ to have between 41 and 83 million lbs of uranium and from 23 to 47 million lbs of molybdenum on its land, according to an independent report by SRK Consulting.
Uranium, coming back into favour as the source of newly-rehabilitated nuclear power, is trading at nearly $40 (£23.5) a lb and molybdenum, a key ingredient of stainless steel, is being sustained by Chinese and Indian demand at around $20 a lb. With ore grades said to be encouraging, SRK says Brinkley’s deposits have an ‘in-ground’ value, before capital and extraction costs, of between £1.25 and £2.35 billion.
Ten per cent of that would be several times Lonrho Africa’s present AIM value of £32 million. But Brinkley’s minerals are by no means the only shot in Lonrho’s locker.
For much of the time since its de-merger from platinum group metals producer Lonmin, the company has been a fairly lacklustre performer, with an assortment of African interests, from plantations to hotels and motor dealerships. Most of these have been divested – including a Toyota franchise sold for £3 million before Lenigas came on board and last month a Kenyan hotels company, which realised £17 million.
Lenigas, who is scathing about the price accepted for the Toyota franchise, wants Lonrho to invest in areas outside mining, although, as a director of entrepreneurial coal group Asia Energy, that is where much of his own experience lies. With £20 million in the kitty from disposals ‘and access to plenty more’, he intends to steer the company into oil and gas, luxury hotels, infrastructure projects and tourism.
Lenigas argues Africa, despite its recent wars and famines, is entering a new era, with Zimbabwe’s Robert Mugabe one of the last relics of the bad old days. He points to the millions available for infrastructure development and tourism projects from international agencies and argues abundant opportunities now exist.
Lonrho’s stated policy is to take ‘substantial’ shareholdings in quoted or private companies so that it can influence their decisions, though smaller stakes are not ruled out. While still seeking to dispose of its remaining ‘residual assets’ from the old days, the company will also participate in joint ventures for appropriate projects.
Lenigas, who recently recruited Ambrian Partners’ mining analyst Emma Priestley to Lonrho’s board, says he has set his sights on building the company into a group with a £1 billion balance sheet. Among those hoping he can pull it off is Blakeney Management, which claims to be one of the largest foreign investors in sub-Saharan Africa and the Arab World.
Blakeney holds around 38 per cent of the company through different funds. Miles Morland, a Blakeney director, has another 13 per cent and asset-minded corporate gadfly Peter Gyllenhammar holds a chunky stake.
Results for the year to September ’05 revealed pre-tax profits of £2.2 million (£4 million) from a total turnover of £5.8 million (£10.1 million). Yet the figures offer little guidance to current prospects.
Lonrho Africa put in a lamentable stock market performance in its old guise, falling from 20p five years ago to 9p in 2004. Signs of possible new life have brought them back
up to 20.5p, where they are a speculative buy.
The Award-winning team at Growth Company Investor produce a complete guide to AIM, providing contact details and financials for every single AIM-quoted company. Click here for more information, and to purchase your copy.
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.